Tafamidis
- Generic Name
- Tafamidis
- Brand Names
- Vyndamax, Vyndaqel
- Drug Type
- Small Molecule
- Chemical Formula
- C14H7Cl2NO3
- CAS Number
- 594839-88-0
- Unique Ingredient Identifier
- 8FG9H9D31J
- Background
Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Tafamidis is structurally similar to diflusinal.
Tafamidis was granted an EMA market authorisation on 16 November 2011 and FDA approval on 3 May 2019.
- Indication
Tafamidis is indicated to treat cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults.
- Associated Conditions
- Cardiomyopathy
To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy
- Conditions
- Transthyretin Amyloid Polyneuropathy
- Interventions
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT06940336
A Study to Compare Two Forms of Study Medicine Tafamidis in the Blood in Healthy Adults
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 22
- Registration Number
- NCT06705569
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy
- Conditions
- Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
- Interventions
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 50
- Registration Number
- NCT06393465
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- Conditions
- Transthyretin Amyloid Cardiomyopathy
- Interventions
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 13
- Registration Number
- NCT06321523
- Locations
- 🇰🇷
Pfizer, Seoul, Korea, Republic of
A Study to Learn How Different Forms of Study Medicine Tafamidis Are Taken Up Into The Blood in Healthy Adults
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT06273839
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Study to Learn About Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in India
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT06086353
- Locations
- 🇮🇳
AIG Hospital, Hyderabad, India
🇮🇳Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bangalore, Karnataka, India
Retrospective Study Collecting Neurological Follow-up of Hereditary Transthyretin Amyloidosis (ATTRv) Patients Included in B3461028 and B3461045.
- Conditions
- Hereditary Transthyretin Amyloidosis (ATTRv)Polyneuropathy
- Interventions
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 5
- Registration Number
- NCT05560555
- Locations
- 🇪🇸
Hospital Clinico San Carlos, Madrid, Spain
🇪🇸Hospital Universitari de Bellvitge, Barcelona, Spain
🇪🇸Hospital Son Llatzer, Palma de Mallorca, Spain
A Study Comparing Two Forms of Tafamidis Without Food and the Amount of Tafamidis in the Blood With Food
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 22
- Registration Number
- NCT05498701
- Locations
- 🇨🇦
Pharma Medica Research Inc, Toronto, Ontario, Canada
Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients with Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT05489523
- Locations
- 🇺🇸
Cedars-Sinai, Beverly Hills, California, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
A Study to Compare Two Tablet Forms of Tafamidis in Healthy Participants
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT05482308
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.